FibroBiologics (FBLG) Amortization of Deferred Charges (2023 - 2026)
FibroBiologics (FBLG) posted quarterly Amortization of Deferred Charges of $95000.0 for Q2 2026, down 34.93% year-over-year from $146000.0 in Q2 2025, and down 44.44% on a QoQ basis from $171000.0 in Q1 2026.
FibroBiologics (FBLG) Amortization of Deferred Charges (2023 - 2026) Analysis & Trends
FibroBiologics has reported Amortization of Deferred Charges for 4 years, with the latest figure at $95000.0 in Q2 2026.
- Amortization of Deferred Charges for Q2 2026 came in at $95000.0, down 34.93% year-over-year; the trailing twelve-month figure through Jun 2026 was $600000.0 (up 29.03% YoY), and the FY2025 annual result was $588000.0, up 41.35% from the prior year.
- Amortization of Deferred Charges eased to $95000.0 in Q2 2026, from $171000.0 in the prior quarter.
- Over five years, Amortization of Deferred Charges peaked at $171000.0 in Q1 2026 and troughed at $95000.0 in Q1 2023.
- A 4-year average of $118571.4 and a median of $104000.0 in 2024 frame the typical range for Amortization of Deferred Charges.
- The widest annual swing landed in 2025, when Amortization of Deferred Charges surged 58.49%; it then tumbled 34.93% in 2026.
- A 4-year view of Amortization of Deferred Charges shows it stood at $99000.0 in 2023, then increased by 7.07% to $106000.0 in 2024, then jumped by 58.49% to $168000.0 in 2025, then tumbled by 43.45% to $95000.0 in 2026.
- Per Business Quant data, the three most recent Amortization of Deferred Charges figures were $95000.0 in Q2 2026, $171000.0 in Q1 2026, and $168000.0 in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | FibroBiologics | 8.97 Mn | 8.97 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 95,000.00 |
| Jun 30, 2026 | 95,000.00 |
| Mar 31, 2026 | 171,000.00 |
| Mar 31, 2026 | 171,000.00 |
| Dec 31, 2025 | 168,000.00 |
| Dec 31, 2025 | 168,000.00 |
| Sep 30, 2025 | 166,000.00 |
| Sep 30, 2025 | 166,000.00 |
| Jun 30, 2025 | 146,000.00 |
| Jun 30, 2025 | 146,000.00 |
| Mar 31, 2025 | 108,000.00 |
| Mar 31, 2025 | 108,000.00 |
| Dec 31, 2024 | 106,000.00 |
| Dec 31, 2024 | 106,000.00 |
| Sep 30, 2024 | 105,000.00 |
| Sep 30, 2024 | 105,000.00 |
| Jun 30, 2024 | 103,000.00 |
| Jun 30, 2024 | 103,000.00 |
| Mar 31, 2024 | 102,000.00 |
| Mar 31, 2024 | 102,000.00 |